Brief: Immix Biopharma Says That 50% Enrollment Has Already Been Surpassed In NEXICART-2
18/09/2025 20:31
Sept 18 (Reuters) - Immix Biopharma Inc IMMX.O: IMMIX BIOPHARMA ANNOUNCES 50% ENROLLMENT MILESTONE SURPASSED IN ITS ONGOING RELAPSED/REFRACTORY AL AMYLOIDOSIS CLINICAL TRIAL, NEXICART-2 Source text: ID:nGNX2hB7RB Further company coverage: IMMX.O (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary